Compare SR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SR | DYN |
|---|---|---|
| Founded | 1857 | 1984 |
| Country | United States | United States |
| Employees | 3497 | N/A |
| Industry | Oil/Gas Transmission | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.9B |
| IPO Year | N/A | 2020 |
| Metric | SR | DYN |
|---|---|---|
| Price | $82.44 | $26.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $91.33 | $37.00 |
| AVG Volume (30 Days) | 475.3K | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $19.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.24 | $8.88 |
| 52 Week High | $95.31 | $25.00 |
| Indicator | SR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 68.05 |
| Support Level | $81.62 | $16.47 |
| Resistance Level | $84.66 | N/A |
| Average True Range (ATR) | 1.64 | 1.43 |
| MACD | 0.37 | -0.02 |
| Stochastic Oscillator | 65.83 | 86.58 |
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.